Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
2.570
+0.020 (0.78%)
At close: Nov 8, 2024, 4:00 PM
2.599
+0.029 (1.13%)
After-hours: Nov 8, 2024, 7:42 PM EST

Company Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.

The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.

It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.

Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics, Inc.
Mersana Therapeutics logo
Country United States
Founded 2001
IPO Date Jun 28, 2017
Industry Biotechnology
Sector Healthcare
Employees 123
CEO Martin Huber

Contact Details

Address:
840 Memorial Drive
Cambridge, Massachusetts 02139
United States
Phone 617 498 0020
Website mersana.com

Stock Details

Ticker Symbol MRSN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001442836
CUSIP Number 59045L106
ISIN Number US59045L1061
SIC Code 2834

Key Executives

Name Position
Dr. Martin H. Huber M.D. President, Chief Executive Officer and Director
Brian C. DeSchuytner Senior Vice President, Chief Financial Officer and Chief Operating Officer
Dr. Timothy B. Lowinger Ph.D. Senior Vice President and Chief Science and Technology Officer
Alejandra Veronica Carvajal J.D. Senior Vice President, Secretary and Chief Legal Officer
Mohan Bala Ph.D. Senior Vice President and Chief Development Officer
Mikhail Papisov Ph.D. Co-Founder
Ashish Mandelia Chief Accounting Officer
Jason Fredette Senior Vice President of Investor Relations and Corporate Communications
Chuck Miller Senior Vice President of Regulatory Affairs
Marc Damelin Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery and Develop.

Latest SEC Filings

Date Type Title
Oct 29, 2024 144 Filing
Oct 15, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 7, 2024 144 Filing
Oct 7, 2024 144 Filing
Oct 7, 2024 144 Filing
Oct 7, 2024 144 Filing
Sep 13, 2024 144 Filing
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jun 11, 2024 8-K Current Report